Scientists reveal the abbreviation of the hidden brain for weight loss without nausea

Nerve cells are the most famous and clear goal in research and drug development for brain conditions. GLP-1 medications, for example, target brain neurons in the background cells involved in appetite control. But researchers look beyond the neurons to study “support” cells such as stroke and stellar cells that can help reduce appetite.

A collaborative research effort revealed that support cells play a role in reducing feelings of hunger, although this process was not studied deeply.

Doyle, a medical chemist, Jack and Laura E, says. Milton, a professor of chemistry at the Faculty of Arts and Sciences at the University of Sri Lips: “We wanted to know whether the support cells may produce new bitdelas or new signals that may be decisive in reducing body weight.” Doyle is also a professor of pharmacy and medicine at New York Medical State University.

How to work

Think about each neuron in the brain as an electric lamp and support cells as ingredients that allow the power lamp to radiance, including wires, switching and strings.

“Everyone who supports the parts that exceed the light bulb play a role in making the glossy light,” says Doyle.

The research team has discovered that some Hindbrain support cells naturally produce a molecule called Octdecanuropeptide (ODN), which suppresses appetite. In laboratory tests, make ODN injection directly into mice brains losing weight and improving how glucose treatment.

However, direct injection into the brain is not a practical treatment for people, so the researchers created a new version of the TRIDECANEUPEPTIDE (TDN). This molecule version can be given to human patients through regular injection that resemble OzemPIC or Zepbound today. When tested in obese mice and musk, TDN helped animals to lose weight and respond better to insulin without causing nausea or vomiting.

Abbreviation

One of the goals of the research team is to produce weight loss without targeting new therapeutic molecules in neurons. The new TDN molecule exceeds the neurons, and takes an acronym for targeting support cells directly to the neurons, which researchers also found a delicious repression. TDN “marathon” cuts from chemical reactions and negative side effects caused by GLP-1.

“Instead of running the marathon race from the beginning, like the current medicines, our targeted paths in the directions of the estuary in support cells are similar to starting the race in the middle of the road, which reduces the unpleasant side effects that many people are exposed to,” says Doyle. “If we can hit the estuary process directly, it is likely that we do not have to use the GLP-1 medications with its side effects. We can reduce their dose, and improve the tolerance of these medications. We can launch weight loss signals that later occur in the path directly.”

A new company called Coronationbio has been launched to convert this discovery into a real treatment. The company has licensed an intellectual ownership related to ODN derivatives to treat obesity and intertwined heart disease from the University of Siraches and the University of Pennsylvania, with a focus on translating candidates into the clinic. They are now cooperating with other companies to develop this treatment and aim to start human experiences in 2026 or 2027.